MA32787B1 - Peptides antiviraux therapeutiques - Google Patents

Peptides antiviraux therapeutiques

Info

Publication number
MA32787B1
MA32787B1 MA33835A MA33835A MA32787B1 MA 32787 B1 MA32787 B1 MA 32787B1 MA 33835 A MA33835 A MA 33835A MA 33835 A MA33835 A MA 33835A MA 32787 B1 MA32787 B1 MA 32787B1
Authority
MA
Morocco
Prior art keywords
therapeutic peptides
antiviral therapeutic
relates
antiviral
drugs
Prior art date
Application number
MA33835A
Other languages
Arabic (ar)
English (en)
Inventor
Scott Seiwert
Leonid Beigelman
Brad Buckman
Vladimir Serebryany
Antitsa Dimitrova Stoycheva
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32787(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of MA32787B1 publication Critical patent/MA32787B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés représentés par la formule 1 décrite ici. L'invention concerne également des procédés thérapeutiques, des compositions, des médicaments, et des formes posologiques y relatives.
MA33835A 2008-10-15 2011-05-11 Peptides antiviraux therapeutiques MA32787B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10574608P 2008-10-15 2008-10-15
US23674109P 2009-08-25 2009-08-25
PCT/US2009/060558 WO2010045266A1 (fr) 2008-10-15 2009-10-13 Peptides antiviraux therapeutiques

Publications (1)

Publication Number Publication Date
MA32787B1 true MA32787B1 (fr) 2011-11-01

Family

ID=41346045

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33835A MA32787B1 (fr) 2008-10-15 2011-05-11 Peptides antiviraux therapeutiques

Country Status (21)

Country Link
US (1) US20100119479A1 (fr)
EP (1) EP2358736A1 (fr)
JP (1) JP2012505897A (fr)
KR (1) KR20110075019A (fr)
CN (1) CN102216321A (fr)
AP (1) AP2011005695A0 (fr)
AR (1) AR073880A1 (fr)
AU (1) AU2009303483A1 (fr)
CA (1) CA2740728A1 (fr)
CL (1) CL2011000846A1 (fr)
CO (1) CO6362017A2 (fr)
EA (1) EA201170441A1 (fr)
EC (1) ECSP11011054A (fr)
IL (1) IL212097A0 (fr)
MA (1) MA32787B1 (fr)
MX (1) MX2011004007A (fr)
NI (1) NI201100076A (fr)
TN (1) TN2011000172A1 (fr)
TW (1) TW201019950A (fr)
WO (1) WO2010045266A1 (fr)
ZA (1) ZA201102822B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
DE602006019323D1 (de) * 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CA2686138A1 (fr) * 2007-05-03 2008-11-13 Intermune, Inc. Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
AR066528A1 (es) * 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
CN102046622A (zh) * 2008-04-15 2011-05-04 因特蒙公司 丙型肝炎病毒复制的新颖大环抑制剂
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
WO2012047764A1 (fr) * 2010-10-04 2012-04-12 Intermune, Inc. Peptides antiviraux thérapeutiques
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34402A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
AU2014233390B2 (en) 2013-03-15 2018-03-01 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis C virus
CN104803918B (zh) * 2014-01-26 2017-11-10 上海医药工业研究院 恩杂鲁胺的制备方法
CN105175491B (zh) * 2015-07-13 2019-01-11 山东大学 一种含有羟脯氨酸骨架的多肽类ns3丝氨酸蛋白酶抑制剂及其制备方法和应用
EP3448392A4 (fr) 2016-04-28 2020-01-15 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5130421A (en) * 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
GB8918806D0 (en) * 1989-08-17 1989-09-27 Shell Int Research Chiral compounds,their preparation and use
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
ES2118069T3 (es) * 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
DE69332616T2 (de) 1992-12-29 2003-11-06 Abbott Lab Hemmer der retroviralen Protease
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
CZ303213B6 (cs) * 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
MXPA03004299A (es) * 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
US7352694B1 (en) * 2001-12-14 2008-04-01 Applied Micro Circuits Corporation System and method for tolerating data link faults in a packet communications switch fabric
CN100381440C (zh) * 2002-04-11 2008-04-16 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂
UA80819C2 (en) * 2002-04-26 2007-11-12 Gilead Sciences Inc Phosphonate analogs of compounds inhibiting hiv proteases, pharmaceutical composition on their basis and their use
WO2004043339A2 (fr) * 2002-05-20 2004-05-27 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
EP1613620A1 (fr) * 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibiteurs des serine proteases, en particulier de la protease ns3-ns4a du vhc
WO2004096285A2 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
TWI280964B (en) * 2003-09-26 2007-05-11 Schering Corp Macrocyclic inhibitors of hepatitis C virus NS3 serine protease
RU2006115558A (ru) * 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2006000085A1 (fr) * 2004-06-28 2006-01-05 Boehringer Ingelheim International Gmbh Analogues peptidiques d'inhibiteurs de l'hepatite c
JP5249028B2 (ja) * 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
EP2402331A1 (fr) * 2005-08-02 2012-01-04 Vertex Pharmaceuticals Incorporated Inhibiteurs des sérines proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DE602006019323D1 (de) * 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2646229A1 (fr) * 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Inhibiteurs de protease de l'hepatite c deuteres
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) * 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010518128A (ja) * 2007-02-16 2010-05-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ｎｓ３プロテアーゼのインヒビター
ES2388315T3 (es) * 2007-05-04 2012-10-11 Bristol-Myers Squibb Company Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
AR066528A1 (es) * 2007-05-10 2009-08-26 Array Biopharma Inc Peptidos inhibidores de la replicacion del virus de la hepatitis c
CA2702724A1 (fr) * 2007-09-04 2009-03-12 Hermes Promethean Ventures Inc. Systeme de distribution de contenus numeriques
AR068756A1 (es) * 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
CN102046622A (zh) * 2008-04-15 2011-05-04 因特蒙公司 丙型肝炎病毒复制的新颖大环抑制剂
CA2734744A1 (fr) * 2008-08-20 2010-02-25 Michael Eissenstat Inhibiteurs de la protease du vhc
US8603737B2 (en) * 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
EP2344487A4 (fr) * 2008-09-23 2012-03-21 Boehringer Ingelheim Int Composés inhibiteurs de l'hépatite c
CA2738477A1 (fr) * 2008-09-24 2010-04-01 Robert S. Kauffman Schema posologique therapeutique comprenant peg-interferon, ribavirine et vx-950 pour le traitement d'une hepatite
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5689810B2 (ja) * 2008-11-20 2015-03-25 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
US20100152103A1 (en) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US8283310B2 (en) * 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100160403A1 (en) * 2008-12-19 2010-06-24 Gilead Sciences, Inc. Hcv ns3 protease inhibitors
CA2746834A1 (fr) * 2008-12-22 2010-07-01 Gilead Sciences, Inc. Composes antiviraux
US20100196321A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Llc Compounds
US8377962B2 (en) * 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI468160B (zh) * 2009-04-25 2015-01-11 Hoffmann La Roche 增進藥物動力學之方法
US20100324059A1 (en) * 2009-06-23 2010-12-23 Gilead Sciences, Inc. Pharmaceutical compositions useful for treating hcv
TW201105323A (en) * 2009-06-23 2011-02-16 Gilead Sciences Inc Pharmaceutical compositions useful for treating HCV
UY32715A (es) * 2009-06-23 2011-01-31 Gilead Sciences Inc Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US20110064694A1 (en) * 2009-09-09 2011-03-17 Yale University Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues
WO2011031904A1 (fr) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Inhibiteurs du virus de l'hépatite c
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) * 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP5702388B2 (ja) * 2009-09-15 2015-04-15 タイゲン バイオテクノロジー カンパニー，リミテッド Ｈｃｖプロテアーゼ阻害剤
JP2013505951A (ja) * 2009-09-28 2013-02-21 エフ．ホフマン−ラ ロシュ エルティーディー Ｃ型肝炎ウイルス複製の新規の大環状インヒビター
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
EP2488526B1 (fr) * 2009-10-14 2013-07-24 Bristol-Myers Squibb Company Composés utiles pour le traitement de l'hépatite c
JP5664471B2 (ja) * 2010-06-28 2015-02-04 信越化学工業株式会社 半導体用合成石英ガラス基板の製造方法

Also Published As

Publication number Publication date
EA201170441A1 (ru) 2012-05-30
AU2009303483A1 (en) 2010-04-22
AR073880A1 (es) 2010-12-09
CN102216321A (zh) 2011-10-12
CA2740728A1 (fr) 2010-04-22
TN2011000172A1 (en) 2012-12-17
MX2011004007A (es) 2011-05-19
US20100119479A1 (en) 2010-05-13
CO6362017A2 (es) 2012-01-20
EP2358736A1 (fr) 2011-08-24
IL212097A0 (en) 2011-06-30
NI201100076A (es) 2012-03-15
TW201019950A (en) 2010-06-01
ECSP11011054A (es) 2011-10-31
JP2012505897A (ja) 2012-03-08
AP2011005695A0 (en) 2011-06-30
ZA201102822B (en) 2011-12-28
CL2011000846A1 (es) 2011-09-30
KR20110075019A (ko) 2011-07-05
WO2010045266A1 (fr) 2010-04-22

Similar Documents

Publication Publication Date Title
MA32787B1 (fr) Peptides antiviraux therapeutiques
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
GEP20146125B (en) Aminopyrimidines as syk inhibitors
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
BRPI0410711A (pt) novos compostos
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MY151295A (en) Pyrimidyl indoline compound
TW200728307A (en) Novel spirochromanone derivatives
EA201070786A1 (ru) Бензофуропиримидиноны
MX2010009646A (es) Agentes terapeuticos antivirales.
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
TW200745122A (en) New compounds I
TW200626158A (en) Naphthaline derivatives
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
JO2937B1 (en) Tight muscles of the peptide vascular tensioner receptor
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
TW200637817A (en) 5-aminoindole derivatives
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique